1190-53-0 | Butyl-biguanidehydrochloride

Packsize	Purity	Availability	Price	Discounted Price
50mg	>95.0%(HPLC)	in stock	$49.00	$34.00
250mg	95%	in stock	$148.00	$104.00

Description

• Catalog Number: AA32212
• Chemical Name: Butyl-biguanidehydrochloride
• CAS Number: 1190-53-0
• Molecular Formula: C6H16ClN5
• Molecular Weight: 193.6777
• MDL Number: MFCD00045591
• SMILES: CCCCNC(=N)NC(=N)N.Cl

Computed Properties

• Complexity: 156
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 12
• Hydrogen Bond Acceptor Count: 1
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 4

Literature

• Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro.

  Toxicology and applied pharmacology 20081201

• Determination of antihyperglycemic biguanides in serum and urine using an ion-pair solid-phase extraction technique followed by HPLC-UV on a pentafluorophenylpropyl column and on an octadecyl column.

  Biomedical chromatography : BMC 20061101

• Buformin suppresses the expression of glyceraldehyde 3-phosphate dehydrogenase.

  Biological & pharmaceutical bulletin 20060501

• Effect of buformin and metformin on formation of advanced glycation end products by methylglyoxal.

  Clinica chimica acta; international journal of clinical chemistry 20050801

• [A case of lactic acidosis caused by buformin in an oldest elderly diabetic patient].

  Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20050301

• [A new case of lactic acidosis caused by buformin].

  Anales de medicina interna (Madrid, Spain : 1984) 20050201

• Short-term effect of buformin, a biguanide, on insulin sensitivity, soluble fraction of tumor necrosis factor receptor and serum lipids in overweight patients with type 2 diabetes mellitus.

  Diabetes research and clinical practice 20041101

• Buformin-induced lactic acidosis--a symptom of modern healthcare malady.

  Journal of the American Geriatrics Society 20041001

• A validated HPLC method with ultraviolet detection for the determination of buformin in plasma.

  Biomedical chromatography : BMC 20040501

• Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone.

  The Journal of clinical endocrinology and metabolism 20030801

• [Lactic acidosis associated with buformine use].

  Revista clinica espanola 20030401

• Insulin and longevity: antidiabetic biguanides as geroprotectors.

  Biogerontology 20030101

• Enhanced secretion of glucagon-like peptide 1 by biguanide compounds.

  Biochemical and biophysical research communications 20021115

• A new method for determination of buformin in plasma and urine by ion-paired reversed-phase HPLC with ultraviolet detection.

  Biomedical chromatography : BMC 20021001

• [Clinical usefulness of treatment with biguanide and insulin].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• Acrylic microspheres for oral controlled release of the biguanide buformin.

  International journal of pharmaceutics 20010507

• Buformin concentrations in a case of fatal lactic acidosis.

  Diabetologia 19810101

• [Lactic acidosis--a possible complication in buformin-treated diabetics (author's transl)].

  Klinische Wochenschrift 19780901